Unlocking the Blood’s Secrets: A New Human Blood Group Discovered
For decades, a mystery lurked within the intricate world of human blood. An unidentified antigen, dubbed AnWj, puzzled scientists for over fifty years. Now, a groundbreaking discovery by researchers at NHS Blood and Transplant and the University of Bristol has finally unveiled the truth – a new human blood group, christened MAL, has been identified.
This momentous finding not only solves the long-standing puzzle surrounding AnWj but also sheds light on the complexity of human genetics and its implications for blood transfusions. Dr. Louise Tilley, Senior Research Scientist at NHS Blood and Transplant, who has dedicated nearly 20 years to unraveling this mystery, expressed her excitement, stating, "The genetic background of AnWj has been a mystery for over 50 years, and one which I personally have been trying to resolve for almost 20 years of my career."
At the heart of this discovery lies a protein called Mal. Researchers discovered that its presence or absence determines whether an individual’s blood cells exhibit the AnWj antigen. Individuals lacking the Mal protein are categorized as AnWj-negative. Receiving blood from an AnWj-positive donor could trigger severe transfusion reactions in these individuals, highlighting the critical need to identify the genetic mutations responsible for Mal protein deficiency.
Professor Ashley Toye, leading research in blood product development at the University of Bristol, explained the significance of this finding: "It’s really exciting that we were able to use our ability to manipulate gene expression in developing blood cells to help confirm the identity of the AnWj blood group." Advanced gene manipulation techniques allowed the team to pinpoint the exact location on the MAL gene responsible for the absence of Mal protein.
The MAL system joins the ranks of the 47th recognized blood group system, further emphasizing the intricate nature of human blood beyond the familiar ABO and Rh systems.
This discovery has important implications for blood banking practices. Nicole Thornton from NHS Blood and Transplant emphasized the need for genotyping tests to identify genetically AnWj-negative patients and donors, stating, "Now, genotyping tests can be designed to identify genetically AnWj-negative patients and donors." These tests are crucial for ensuring suitable blood matches and preventing adverse reactions in patients with rare blood types.
The breakthrough was achieved through exome sequencing, a modern genetic tool focused on protein-coding regions of DNA. This technology enabled researchers to quickly isolate the specific DNA segment responsible for the AnWj antigen anomaly. Dr. Tim Satchwell from UWE Bristol acknowledged the challenges they faced, stating, "Mal is a very small protein with some interesting properties, which made it difficult to identify. We needed to pursue multiple lines of investigation to accumulate the proof required to establish this blood group system."
While individuals lacking AnWj are rare, their unique blood type requires careful attention. The identification of the MAL system ensures that medical professionals can take necessary precautions and locate compatible donors, preventing potentially harmful transfusion reactions.
Dr. Tilley concluded, "This represents a huge achievement and the culmination of a long team effort to finally establish this new blood group system and offer the best care to rare but important patients,"